title: Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.
abstract: Treatment of Chronic Myeloid Leukaemia (CML) has evolved rapidly in the last 10 years. The objectives of this national consensus meeting were to describe the optimal procedures to perform at diagnosis, the most appropriate choice of tyrosine kinase inhibitor (TKI) in the first line setting, the correct monitoring procedures, the appropriate timing for resistance identification allowing a rapid TKI switch, and the future possibility of treatment discontinuation. A panel of experts in CML management were invited for a 2-day workshop. Prior to the conference, the organizing committee selected several topics and assigned them to different physicians divided in four groups. Issues discussed were (1) role of cytogenetic and molecular response monitoring in 2013; (2) frontline treatment of CML in 2013 and therapeutic objectives; (3) how to monitor response and when to change therapy after resistance or non-optimal responses; (4) possible therapy discontinuation after achievement of deep and stable molecular responses. Different national experts reviewed the literature, analyzed levels of evidence for each topic and, after extensive discussions within smaller working groups, presented their conclusions during the meeting. Each consensus aim was then evaluated by a general vote in the plenary sessions.
authors.affiliation: Department of Biotechnologies and Cellular Hematology, Sapienza University, Rome, Italy. Electronic address: breccia@bce.uniroma1.it.
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.affiliation: Department of Biotechnologies and Cellular Hematology, Sapienza University, Rome, Italy.
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
authors.affiliation: Hematology, Policlinico S. Orsola, Bologna, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
authors.affiliation: Department of Hematology, University of Siena, Italy.
authors.forename: Monica
authors.initials: M
authors.lastname: Bocchia
authors.affiliation: Department of Clinical and Molecular Bio-Medicine, Section of Hematology and Oncology, University of Catania, Catania, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Raimondo
authors.affiliation: Department of Health Sciences, University of Milano, Bicocca, Monza, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: Gambacorti-Passerini
authors.affiliation: Functional Unit of Hematology, University of Florence, Italy.
authors.forename: Antonella
authors.initials: A
authors.lastname: Gozzini
authors.affiliation: Division of Haematology, Niguarda Hospital, Milan, Italy.
authors.forename: Enrica
authors.initials: E
authors.lastname: Morra
authors.affiliation: CEINGE Biotecnologie Avanzate, Naples, Italy.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Pane
authors.affiliation: Hematology 2, San Giovanni Battista Hospital and University, Turin, Italy.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Pregno
authors.affiliation: Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Orbassano, Italy.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Rege-Cambrin
authors.affiliation: Hematology, Policlinico S. Orsola, Bologna, Italy.
authors.forename: Gianantonio
authors.initials: G
authors.lastname: Rosti
authors.affiliation: Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section University of Bari, Italy.
authors.forename: Giorgina
authors.initials: G
authors.lastname: Specchia
authors.affiliation: Department of Clinical and Molecular Bio-Medicine, Section of Hematology and Oncology, University of Catania, Catania, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Vigneri
authors.affiliation: Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Orbassano, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Saglio
mesh_terms: D019468:Disease Management; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000628:therapy*; D016896:Treatment Outcome
keywords: Chronic myeloid leukaemia; Monitoring; Therapeutic objectives; Treatment discontinuation